You are currently viewing our desktop site, do you want to download our app instead?
Moneyweb Android App Moneyweb iOS App Moneyweb Mobile Web App

NEW SENS search and JSE share prices

More about the app

J&J may follow ImmunityBio’s SA Covid booster shot trial

Talks are underway with Johnson & Johnson about running a booster trial in South Africa.
Image: Pavlo Gonchar / SOPA Images/Sipa USA

Talks are underway with Johnson & Johnson about running a booster trial in South Africa after the company’s Covid-19 vaccine was used in a mass trial of almost half a million health workers in the country.

The trial would include participants from that study, known as Sisonke, and could possibly start in October, according to Glenda Gray, who is co-lead of the mass trial. It would add to a booster study in the country using ImmunityBio Inc.’s shot that has already started.

Moneyweb Insider INSIDERGOLD

Subscribe for full access to all our share and unit trust data tools, our award-winning articles, and support quality journalism in the process.

Choose an option:

R63 per month
R630 per year SAVE R126

You will be redirected to a checkout page.
To view all features and options, click here.

A monthly subscription is charged pro rata, based on the day of purchase. This is non-refundable and includes a R5 once-off sign-up fee.
A yearly subscription is refundable within 14 days of purchase and includes a 365-day membership.

Click here for more information.

South Africa, where scientists believe that about a quarter of a million people have died of Covid-19, has hosted vaccine trials for companies including Novavax Inc., Pfizer Inc., AstraZeneca Plc and J&J. The country is currently exiting its third wave of infections with another resurgence expected later this year.

“We are talking to J&J and the department of health about the feasibility of a boost,” said Gray, who is also the president of the South African Medical Research Council. “We would like to start that in October, in time for the fourth wave.”

A number of the world’s richest countries have started giving some of their citizens additional shots with the aim of bolstering the immune response against the virus several months after their initial inoculation, as the number of antibodies may wane.

While ImmunityBio’s trial is in its first phase, with about 50 participants, it is expected to reach its third and final stage in October, with about 10 000 people receiving doses, she said.

© 2021 Bloomberg

COMMENTS   0

You must be signed in to comment.

SIGN IN SIGN UP

LATEST CURRENCIES  

USD / ZAR
GBP / ZAR
EUR / ZAR
BTC / USD

Podcasts

INSIDER SUBSCRIPTIONS APP VIDEOS RADIO / LISTEN LIVE SHOP OFFERS WEBINARS NEWSLETTERS TRENDING PORTFOLIO TOOL CPD HUB

Follow us: